Microvascular interventional device dev Micro Medical Solutions said today it won CE Mark approval in the European Union for its MicroStent vascular stent designed for treating patients with peripheral artery disease.
The Wilmington, Mass.-based company’s MicroStent is designed to reduce below-the-knee amputations for individuals with PAD resulting in critical limb ischemia.
“The MicroStent is the centerpiece of an integrated delivery platform that will help fill an unmet need in the interventional community. Amputation prevention in this CLI patient population is an ongoing fight, and we welcome new tools that have such promise to make a difference,” said Dr. Jihad Mustapha said in a prepared statement.
The MicroStent is part of the company’s MMS Micro Vascular Integrated Platform, which also includes the MicroBalloon and MicroGuide, and is designed to treating CLI lesions below the knee. The MicroBalloon and MicroGuide have already obtained FDA and CE Mark clearance.
“This major milestone for MMS brings our Micro Vascular Integrated Platform, which includes MicroStent, one step closer to becoming available to European physicians. We are delighted to share this exciting news with interventionists, who are seeking much-needed innovation in this underserved area,” CEO Gregory Sullivan said in a press release.